Effect of roflumilast on airway remodelling in a murine model of chronic asthma

Clinical and Experimental Allergy

Volumn 46, Issue 5, 2016, Pages 754-763

  Kim, S W ^a   Kim, J H ^a   Park, C K ^a   Kim, T J ^a   Lee, S Y ^a   Kim, Y K ^a   Kwon, S S ^a   Rhee, C K ^a   Yoon, H K ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Airway inflammation; Airway remodelling; Asthma; Roflumilast

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; MESSENGER RNA; ROFLUMILAST; STEM CELL FACTOR; ALLERGEN; AMINOPYRIDINE DERIVATIVE; ANTIASTHMATIC AGENT; BENZAMIDE DERIVATIVE; CYCLOPROPANE DERIVATIVE; CYTOKINE; HYDROXYPROLINE; IMMUNOGLOBULIN E;

AIRWAY REMODELING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; CELL HYPERPLASIA; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; FETUS; FIBROBLAST; GENE EXPRESSION; GOBLET CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG FIBROSIS; LUNG LAVAGE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFLAMMATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; BRONCHOALVEOLAR LAVAGE FLUID; CHRONIC DISEASE; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; LUNG; METABOLISM; MOUSE; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION;

AIRWAY REMODELING; ALLERGENS; AMINOPYRIDINES; ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; BENZAMIDES; BRONCHOALVEOLAR LAVAGE FLUID; CHRONIC DISEASE; CYCLOPROPANES; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GOBLET CELLS; HUMANS; HYDROXYPROLINE; IMMUNOGLOBULIN E; LUNG; MICE; MICE, INBRED BALB C; PULMONARY FIBROSIS; RESPIRATORY HYPERSENSITIVITY; T-LYMPHOCYTE SUBSETS;

EID: 84964345054     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12670     Document Type: Article

References (45)

1. Olin JT, Wechsler ME. Asthma: pathogenesis and novel drugs for treatment. BMJ 2014; 349:g5517.
2. Shifren A, Witt C, Christie C, Castro M. Mechanisms of remodeling in asthmatic airways. J Allergy (Cairo) 2012; 2012:316049.
3. Homer RJ, Elias JA. Airway remodeling in asthma: therapeutic implications of mechanisms. Physiology (Bethesda) 2005; 20:28-35.
4. Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 2001; 164:S28-38.
5. Trevor JL, Deshane JS. Refractory asthma: mechanisms, targets, and therapy. Allergy 2014; 69:817-27.
6. Bergeron C, Tulic MK, Hamid Q. Airway remodelling in asthma: from benchside to clinical practice. Can Respir J 2010; 17:e85-93.
7. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998; 339:1194-200.
8. Al-Muhsen S, Johnson JR, Hamid Q. Remodeling in asthma. J Allergy Clin Immunol 2011; 128:451-62; quiz 463-454.
9. Warner SM, Knight DA. Airway modeling and remodeling in the pathogenesis of asthma. Curr Opin Allergy Clin Immunol 2008; 8:44-8.
10. Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 2013; 131:636-45.
11. Hatzelmann A, Morcillo EJ, Lungarella G et al. The preclinical pharmacology of roflumilast-a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2010; 23:235-56.
12. Calverley PM, Martinez FJ, Fabbri LM, Goehring UM, Rabe KF. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol. Int J Chron Obstruct Pulmon Dis 2012; 7:375-82.
13. Field SK. Roflumilast, a novel phosphodiesterase 4 inhibitor, for COPD patients with a history of exacerbations. Clin Med Insights Circ Respir Pulm Med 2011; 5:57-70.
14. Herbert C, Hettiaratchi A, Webb DC, Thomas PS, Foster PS, Kumar RK. Suppression of cytokine expression by roflumilast and dexamethasone in a model of chronic asthma. Clin Exp Allergy 2008; 38:847-56.
15. Louw C, Williams Z, Venter L et al. Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge. Respiration 2007; 74:411-7.
16. Bateman ED, Izquierdo JL, Harnest U et al. Efficacy and safety of roflumilast in the treatment of asthma. Ann Allergy Asthma Immunol 2006; 96:679-86.
17. Gauvreau GM, Boulet LP, Schmid-Wirlitsch C et al. Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects. Respir Res 2011; 12:140.
18. Wu W, Chen H, Li YM, Wang SY, Diao X, Liu KG. Intranasal sirna targeting c-kit reduces airway inflammation in experimental allergic asthma. Int J Clin Exp Pathol 2014; 7:5505-14.
19. Kumar RK, Herbert C, Thomas PS et al. Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma. J Pharmacol Exp Ther 2003; 307:349-55.
20. Tanaka H, Masuda T, Tokuoka S et al. The effect of allergen-induced airway inflammation on airway remodeling in a murine model of allergic asthma. Inflamm Res 2001; 50:616-24.
21. Padrid P, Snook S, Finucane T et al. Persistent airway hyperresponsiveness and histologic alterations after chronic antigen challenge in cats. Am J Respir Crit Care Med 1995; 151:184-93.
22. Kang JY, Lee SY, Rhee CK, Kim SJ, Kwon SS, Kim YK. Effect of aging on airway remodeling and muscarinic receptors in a murine acute asthma model. Clin Interv Aging 2013; 8:1393-403.
23. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000; 161:1720-45.
24. Boulet LP, Sterk PJ. Airway remodelling: the future. Eur Respir J 2007; 30:831-4.
25. Rhee CK, Kim JW, Park CK et al. Effect of imatinib on airway smooth muscle thickening in a murine model of chronic asthma. Int Arch Allergy Immunol 2011; 155:243-51.
26. Barnes PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 2003; 167:813-8.
27. Barnes PJ. Theophylline for COPD. Thorax 2006; 61:742-4.
28. Barnes PJ. Theophylline. Am J Respir Crit Care Med 2013; 188:901-6.
29. Lipworth B. Phosphodiesterase type 4 inhibitors for asthma: a real breakthrough or just expensive theophylline? Ann Allergy Asthma Immunol 2006; 96:640-2.
30. Grootendorst DC, Gauw SA, Verhoosel RM et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007; 62:1081-7.
31. Brightling CE, Symon FA, Birring SS, Bradding P, Pavord ID, Wardlaw AJ. TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis. J Allergy Clin Immunol 2002; 110:899-905.
32. Robinson DS, Hamid Q, Ying S et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326:298-304.
33. Kudo M, Ishigatsubo Y, Aoki I. Pathology of asthma. Front Microbiol 2013; 4:263.
34. Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev 2010; 19:46-54.
35. Al-Alawi M, Hassan T, Chotirmall SH. Transforming growth factor beta and severe asthma: a perfect storm. Respir Med 2014; 108:1409-23.
36. Al-Muhsen SZ, Shablovsky G, Olivenstein R, Mazer B, Hamid Q. The expression of stem cell factor and c-kit receptor in human asthmatic airways. Clin Exp Allergy 2004; 34:911-6.
37. Reber L, Da Silva CA, Frossard N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol 2006; 533:327-40.
38. Dolgachev VA, Ullenbruch MR, Lukacs NW, Phan SH. Role of stem cell factor and bone marrow-derived fibroblasts in airway remodeling. Am J Pathol 2009; 174:390-400.
39. Rhee CK, Kang JY, Park CK et al. Effect of nilotinib on airway remodeling in a murine model of chronic asthma. Exp Lung Res 2014; 40:199-210.
40. Berlin AA, Hogaboam CM, Lukacs NW. Inhibition of SCF attenuates peribronchial remodeling in chronic cockroach allergen-induced asthma. Lab Invest 2006; 86:557-65.
41. Berlin AA, Lincoln P, Tomkinson A, Lukacs NW. Inhibition of stem cell factor reduces pulmonary cytokine levels during allergic airway responses. Clin Exp Immunol 2004; 136:15-20.
42. Finotto S, Buerke M, Lingnau K, Schmitt E, Galle PR, Neurath MF. Local administration of antisense phosphorothioate oligonucleotides to the c-kit ligand, stem cell factor, suppresses airway inflammation and IL-4 production in a murine model of asthma. J Allergy Clin Immunol 2001; 107:279-86.
43. Berlin AA, Lukacs NW. Treatment of cockroach allergen asthma model with imatinib attenuates airway responses. Am J Respir Crit Care Med 2005; 171:35-9.
44. Huang M, Liu X, Du Q, Yao X, Yin KS. Inhibitory effects of sunitinib on ovalbumin-induced chronic experimental asthma in mice. Chin Med J (Engl) 2009; 122:1061-6.
45. Dolgachev V, Berlin AA, Lukacs NW. Eosinophil activation of fibroblasts from chronic allergen-induced disease utilizes stem cell factor for phenotypic changes. Am J Pathol 2008; 172:68-76.